Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Dec 2024 value amounting to $53.8 million.

  • Catalyst Pharmaceuticals' Change in Accured Expenses fell 33.95% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.9 million, marking a year-over-year decrease of 47.58%. This contributed to the annual value of $53.8 million for FY2024, which is 828.41% up from last year.
  • According to the latest figures from FY2024, Catalyst Pharmaceuticals' Change in Accured Expenses is $53.8 million, which was up 828.41% from $5.8 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Change in Accured Expenses registered a high of $53.8 million during FY2024, and its lowest value of -$1.2 million during FY2020.
  • Its 3-year average for Change in Accured Expenses is $25.3 million, with a median of $16.4 million in 2022.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first slumped by 109.64% in 2020, then spiked by 828.41% in 2024.
  • Catalyst Pharmaceuticals' Change in Accured Expenses (Yearly) stood at -$1.2 million in 2020, then spiked by 556.58% to $5.5 million in 2021, then soared by 196.94% to $16.4 million in 2022, then plummeted by 64.61% to $5.8 million in 2023, then skyrocketed by 828.41% to $53.8 million in 2024.